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Summary
Infection withChlamydia pneumoniae (Cp) accounts for around 10% of com-
munity acquired bacterial pneumonia and has been associated with other
chronic inflammatory conditions.We describe a C57/Bl6 murine model of Cp
lung infection characterized by a dose-dependent, resolving neutrophilia fol-
lowed by lymphocytic infiltration of the lungs. By 21 days post-infection,mice
exhibit a T helper type 1 (Th1) polarized serum antibody response with local
mucosal antibody secretion and organization of ectopic lymphoid tissue
which persisted in the absence of detectable Cp DNA.Macrophage inflamma-
tory protein (MIP)-2/CXCL2, which recruits neutrophils and lymphocytes
and is associated with ectopic lymphoid tissue formation, was secreted in the
lungs post-infection. In vitro, lung epithelial cells up-regulated MIP-2/CXCL2
in response to both rough lipopolysaccharide (reLPS) and Cp infection. We
conclude that Cp infection can have long-term inflammatory effects on tissue
that persist after clearance of active infection.
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Introduction
Chlamydia pneumoniae (Cp), an obligate intracellular bac-
terium, is a ubiquitous human pathogen [1]. Cp infection
accounts for around 10% of community acquired bacterial
pneumonia and has been associated with chronic lung dis-
eases including chronic bronchitis [2], asthma [1] and
chronic obstructive pulmonary disease (COPD) [3] and
other chronic pathologies, including multiple sclerosis [4],
atherosclerosis [5] and Alzheimer’s disease [6]. Despite these
associations, antibiotic therapy does not have a major clini-
cal benefit in these disorders [7–9], and where an effect has
been observed, such as with macrolides [10,11] it is unclear
if this is due to anti-microbial or anti-inflammatory effects
[12]. It is possible that pulmonary Cp infection initiates an
inflammatory environment which persists after bacterial
clearance and contributes to infection-associated pathology.
Several murine models of Cp ‘vaccination’, infection and
reinfection have been published [13–15] and have estab-
lished that Cp infects lung epithelial cells and induces lung
inflammation, ectopic lymphoid tissue formation and
airway hyper-reactivity. However, there is little information
on how resolution of infection relates to inflammation-
induced disruption of lung architecture which may contrib-
ute to pathology.
We investigated a link between cytokine production by
Cp-infected lung epithelial cells and inflammation. The
chemokine macrophage inflammatory protein (MIP)-2/
CXCL2 recruits both neutrophils and lymphocytes [16–18]
and is associated with ectopic lymphoid tissue formation
[19]. It has been reported that epithelial cell secretion of
MIP-2/CXCL2 recruits both lymphocytes and neutrophils to
the gut [18]. Here we report that murine Cp lung infection
induced systemic T helper type 1 (Th1)-driven immunity,
local mucosal antibody secretion and initiated organization
of ectopic lymphoid tissue which persisted in the absence of
detectable Cp DNA. We demonstrated that MIP-2/CXCL2
was secreted in the lungs post-infection (PI). Furthermore,
in vitro studies utilizing lung epithelial cell lines demon-
strated up-regulation of MIP-2/CXCL2 in response to both
Cp infection and to a rough form of LPS (reLPS) analogous
to that expressed by Cp.
Materials and methods
Reagents and plastics
Unless stated, plastics were from Costar (Fisher Scientific,
Loughborough, UK), culture reagents from Invitrogen
(Paisley, UK) and other reagents from Sigma (Poole, UK).
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Bacteria
HEp2 cell (ECACC, Salisbury, UK) monolayers were washed
and incubated with diethylaminoethyl (DEAE)-dextran
30 mg/ml in Hanks’ balanced salt solution (HBSS) (20 min,
room temperature). DEAE-dextran/HBSS was removed and
Cp AR39 strain (ATCC 53592) in infection medium [5% fetal
calf serum (FCS)/Iscove’s modified Dulbecco’s medium
(IMDM)/1 mg/ml cycloheximide] added for 3 h and then
replaced with fresh infection medium alone. Infected mono-
layers were disrupted manually with glass beads. The suspen-
sion was centrifuged at 200 g/10 min/4°C, the supernatant
centrifuged further at 22 000 g/40 min/4°C, the resulting
pellet resuspended in sucrose–phosphate–glutamate buffer
[20] medium and stored at -80°C. Uninfected HEp2 lysate
was used as a control. Stocks were titrated in Hep2 cells as
described for C. abortus [21]. Titres of stocks were 7 ¥ 107–108
inclusion-forming units (IFU)/ml. Cp were inactivated by
exposure to 2 mJ/cm2 under an ultraviolet (UV)-cross-linker.
In vivo infection
Six to 8-week-old C57Bl/6 mice, bred and maintained under
standard specific pathogen-free conditions, were used with
local ethical and UK Home Office approval. Fifty ml
phosphate-buffered saline (PBS), containing live or
UV-inactivated Cp, or control lysate, was instilled into the
trachea under anaesthetic. Mice were killed at various times
PI. As described [22], blood was taken; bronchoalveolar
lavage fluid (BALF) collected; lungs were perfused with
PBS via the heart, removed, inflated with and placed into
methacarn fixative overnight before processing and wax
embedding. Serum was aliquoted and stored at -20°C until
use. For studies involving Cp DNA detection, lungs were
processed as above, with the exception that the single left
lobe was tied off and excised for DNA extraction prior to
inflation of the right lobes with fixative for immunohis-
tochemistry and histology.
Cp DNA detection
DNA was extracted (Wizard genomic DNA purification kits;
Promega, Southampton, UK) from homogenized lung lobes
(TissueLyser, Qiagen, Crawley, UK) and run on an Applied
Biosystems (Warrington, UK) 7500 real-time polymerase
chain reaction (PCR) machine as duplicate single reactions
using Applied Biosystems mastermix for host 18S primers
and Cp 23S primers and probes [23]. Ct values were used to
generate a relative ratio between DNA for bacterial 23S
rRNA and host 18S rRNA.
Inflammation in BALF
BALF was centrifuged at 300 g/5 min/4°C, supernatant
removed and stored at -20°C. Cells were counted, cytospins
spun (Shandon cytocentrifuge; Fisher Scientific), methanol-
fixed, stained with DiffQuik (CellPath Store, Powys, UK) and
differential cell counts performed by an observer blinded to
experimental details (S. E. M. H.).
Immunohistochemistry (IHC)
Three-mm sections were dewaxed, rehydrated, blocked
with 3% H2O2 in methanol (5 min, room temperature)
and antigen retrieved (Borg decloaker; Biocare Medical,
Concord, CA, USA). For IHC with mouse monoclonal anti-
body, Vector Laboratories’ (Peterborough, UK) mouse-on-
mouse kit was used. Slides in Shandon Sequenza™ staining
clips (Fisher Scientific) were washed, primary antibody
(1:100 goat anti-murine MIP-2/CXCL2 antibody, R&D
Systems, Abingdon, UK; 1:50 rat anti-mouse IgA, 1:125 rat
anti-mouse B220, 1:300 rat anti-mouse CD138, all BD Bio-
sciences, Oxford, UK; 1:200 rabbit anti-CD3 antibody, Dako,
Ely, UK; 1:1000 mouse monoclonal anti-LPS antibody, clone
13/4, in-house [24]) or diluent control added (overnight
4°C), washed, 1:250 biotinylated secondary antibody (swine
anti-rabbit IgG, rabbit anti-goat IgG, rabbit anti-mouse IgG,
all Dako; goat anti-rat IgG, Vector Laboratories) added (1 h,
room temperature), washed, streptavidin–horseradish per-
oxidase (HRP) (Dako) added, washed, and staining visual-
ized with diaminobenzidine substrate solution (Dako).
Assessment of lung inflammation
As described [22], inflammation was scored by an observer
blinded to experimental details (S. E. M. H.) in perivascular
and peribronchiolar tissue (1 = 0, 2 = < 20, 3 = > 20 < 100
and 4 = > 100 infiltrating cells) on haematoxylin and eosin
(H&E)-stained 3-mm sections at ¥200 magnification by aver-
aging the score of 10 consecutive fields where the lungs were
inflated correctly and the field contained a complete transec-
tion of at least one bronchiole (< 300 mm diameter). Neu-
trophilia was determined as percentage of infiltrating cells.
Enzyme-linked immunosorbent assay (ELISA) for
rough LPS antibodies
Antibodies to Cp rough LPS (reLPS) are cross-reactive with
Salmonella minnesota reLPS [25], which was used to measure
antibody responses to infection. Ninety-six-well ELISA
plates were coated with 100 ng/well reLPS in pH9·6
carbonate/bicarbonate buffer (overnight, 4°C), washed,
blocked (1 h, room temperature) with 1% bovine serum
albumin (BSA), washed, serum or BALF dilutions added
(overnight, 4°C), washed, biotinylated anti-mouse immuno-
globulin IgG1 (Serotec, Oxford, UK), biotinylated anti-
mouse IgG2ab or biotinylated anti-mouse IgA (both BD
Biosciences) added (1 h, room temperature), washed,
streptavidin-HRP (R&D Systems) added (1 h, room tem-
perature), washed and substrate (hydrogen peroxide/
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tetramethylbenzidine; R&D Systems) added (30 min, 37°C,
in the dark). The reaction was stopped by addition of 2 N
H2SO4 and plates read at 450 nm (650 nm reference) on a
Biotek Synergy HT plate reader (Fisher Scientific).
In vitro LPS treatment and infection
Cells were cultured in a humidified incubator at 37°C in 5%
CO2. Mycoplasma-free, C57Bl/6 derived pulmonary epithe-
lial cell lines, mtCC1-2 [26] and CMT64/61 (ECACC) were
maintained in antibiotic-free IMDM containing 10% FCS
and 1% L-glutamine (complete IMDM); 250 ml complete
IMDM, containing 2·5 ¥ 105 cells, was plated into 48-well
plates, cultured for 24 h, medium removed, fresh medium
containing reLPS (10 mg/ml), or Cp (at MOI 10), or control
lysate, added to triplicate wells and cultured for various
times.
MIP-2/CXCL2-2 protein and m-RNA detection
MIP-2/CXCL2 protein was detected using R&D Systems
murine Duoset ELISA. RNA (extracted using RNeasy micro-
kit; Qiagen) was run in triplicate multiplex reactions (25 ml
containing TaqMan reagents and 40 ng cDNA) in an Applied
Biosystems 7500 real-time PCR machine. Gene expression
normalized to 18SRNA was linearized to give fold change
relative to a value of 1 assigned to expression in cultures
grown in medium alone.
Statistics
Results were analysed by unpaired t-test with Welch’s cor-
rection using Graphpad Prism™ software.
Results
In vivo infection
Dose-dependent BALF neutrophilia was resolving by day 6
PI, whereas the % of lymphocytes, although small, increased
from day 3 to day 6 (Fig. 1a–c). Subsequently a dose of
2·5 ¥ 106 IU was used; this induced severe neutrophilia
which was not seen with UV-inactivated Cp (Fig. 1d). BALF
neutrophilia 3 days PI correlated with chlamydial 23S DNA
in lungs from the same animals (Fig. 1e). Bacterial DNA
declined after infection and by 21 days PI was undetectable
in five of 10 animals (Fig. 1f).
Cp lung infection induces systemic IgG2a and local IgA
antibody
Twenty-one days PI, high-titre anti-reLPS IgG2a, but not
IgG1, antibodies were detected in serum from infected mice
(Fig. 2a,b). There were no detectable anti-reLPS serum IgA
antibodies, but high levels were seen in BALF from infected
mice (Fig. 2c).
Kinetics of the inflammatory response to Cp infection
in lung tissue
Sham-infected mice showed no inflammation at any time, so
sham data have been pooled. Figure 3a–g shows inflamma-
tion in BALF where total cells and neutrophilia peaked 3 days
PI and returned to normal by 21 days PI whereas lympho-
cytes remained raised 21 days PI. The macrophage number
did not differ from the sham-infected controls. Levels of the
macrophage chemokine MCP-1 did not differ between BALF
from infected or uninfected animals (not shown).
Fig. 1. Bronchoalveolar fluid (BALF)
macrophages (a), neutrophils (b) and
lymphocytes (c) 3 days (clear bars) and 6 days
(black bars) post-infection (PI). (d)
Neutrophilia in BALF 3 days PI with 2·5 ¥ 106
live, but not ultraviolet (UV)-inactivated,
international units (IU) Cp. ***P < 0·001
compared to UV-inactivated Chlamydia
pneumoniae (Cp) and to sham. (e) Degree of
neutrophilia (white bars) in three representative
mice 3 days PI with 2·5 ¥ 106 IU correlates with
detection of Cp DNA in lung tissue (black
diamonds). (f) Detection of Cp DNA in lung
tissue at various times PI.
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Inflammation in lung interstitium (Fig. 3h–j) also showed
neutrophilia that peaked on day 3 and resolved by day 21 PI.
In contrast, perivascular and peribronchiolar inflammation
did not resolve by day 21 PI.
Cp infection induces formation of ectopic
lymphoid tissue
Lungs from mice 21 days PI showed multiple, patchy lym-
phocytic aggregates. The percentage of blood vessels (mean
number/section, 78 7) and bronchioles (mean number/
section, 34 4) associated with > 10 T lymphocytes (on
anti-CD3 stained sections) and with > 10 B lymphocytes (on
anti-B220 stained sections) were determined. The percent-
age of blood vessels or bronchioles associated with either cell
type was < 1 for sham-infected mice, whereas 30–40% of
blood vessels and 10–20% of bronchioles in infected mice
had associated lymphoid aggregates (Fig. 4a,b). Many aggre-
gates were large, morphologically resembled germinal
centres (Fig. 4c,d) and contained clusters of B lymphocytes
(Fig. 4e) and scattered T lymphocytes (Fig. 4f). Large
numbers of cells were positive for IgA (Fig. 4g) and staining
for CD138 (a marker of antibody secreting plasma cells and
of lung bronchiolar epithelial cells [27,28]) revealed positive
plasma cells indicating ectopic lymphoid tissue formation
(Fig. 4h).
Lymphoid aggregates, anti-reLPS antibodies and
lymphocytes in BAL do not correlate with detection of
23S chlamydial DNA
Twenty-one days PI, approximately half the mice had no
detectable chlamydial 23S DNA in the lungs. There were no
differences between IgA in BALF, IgG2a in serum (Fig. 5a),
total BALF lymphocytes (Fig. 5b) or distribution of lym-
phoid aggregates (Fig. 5c,d) in mice that were positive or
negative for detection of chlamydial 23S DNA in the lungs 21
days PI.
Fig. 2. Anti-rough lipopolysaccharide (reLPS)
antibodies 21 days post-infection (PI).
Immunoglobulin (Ig)G1 (a) and IgG2a
antibodies (b) in serum [dotted lines
Chlamydia pneumoniae (Cp)-infected, solid
lines sham-infected mice]. (c) Bronchoalveolar
fluid (BALF) and serum (all at 1:30 dilution)
IgA antibodies. Sham, n = 8; Cp-infected,
n = 10; ***P < 0·001; **P < 0·01; *P < 0·05
compared to sham controls.
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Fig. 3. Kinetics of lung inflammation. (a–c)
representative bronchoalveolar fluid (BALF)
cytospins, (a) 3 days after sham infection; (b) 3
days post-infection (PI); (c) 21 days PI;
bar = 15 mm. (d–g) cells in BALF 1, 3, 6 and 21
days PI compared to pooled sham-infected
mice. The majority of sham-infected animals
had no detectable lymphocytes or neutrophils
in BAL; (d) total cells; (e) total neutrophils; (f)
total macrophages; (g) total lymphocytes; (h)
perivascular and (i) peribronchiolar lung
inflammation scores; (j) neutrophilia in
pulmonary tissue. *P < 0·05; **P < 0·01;
***P < 0·001 compared to sham-infected.
Pooled data from four experiments.
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Infected lungs and airway epithelial cells secrete
MIP-2/CXCL2 in response to reLPS and Cp infection
The principal site of infection detected by anti-LPS staining
was bronchial epithelial cells (BECs) (Fig. 6a). At 3 days PI,
both BECs and alveolar cells contained MIP-2/CXCL2
(Fig. 6b) but at 21 days PI only BECs were positive (Fig. 6c).
MIP-2/CXCL2 protein was detected in BALF 1, 3 and 6 days
PI (Fig. 6d).
In vitro, reLPS induced upregulation of MIP-2/CXCL2
mRNA (Fig. 6e) and protein secretion (Fig. 6f) in two differ-
ent mouse lung epithelial cell lines. Protein secretion also
increased in response to Cp infection (Fig. 6g).
Discussion
Pulmonary Cp infection induced a dose-dependent, resolv-
ing neutrophilia followed by a lymphocytic lung infiltration.
Fig. 4. Distribution of T (a) and B lymphocytes
(b) around pulmonary blood vessels and
bronchioles 21 days post-infection (PI);
sham-infected mice < 1% for all values.
*P < 0·05; **P < 0·01; ***P < 0·001, compared to
sham-infected, pooled data from four
experiments. (c) Representative low-power
haematoxylin and eosin (H&E), lymphoid
aggregates circled. (d) High-power H&E of a
single aggregate. (e–i) Representative
immunohistochemistry of lung aggregates
stained with (e) anti-B220; (f) anti-CD3; (g)
anti-immunoglobulin (Ig)A; (h) anti-CD138
(which is also expressed by lung epithelial cells,
arrowed); (i) no-primary antibody control.
Bars = 100 mm.
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Fig. 5. 23S DNA-positive (black circles) and -negative (open circles) lungs. (a) Bronchoalveolar fluid (BALF) immunoglobulin (Ig)A (1:30 dilution)
and serum IgG2a (1:300 dilution) anti-rough lipopolysaccharide (reLPS) antibody enzyme-linked immunosorbent assay. (b) Total number of
lymphocytes in BALF. (c) Percentage of bronchioles associated with lymphoid aggregates. (d) Percentage of lung blood vessels associated with
lymphoid aggregates. Each circle represents an individual mouse.
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Macrophages in BALF did not change, indicating that mac-
rophage recruitment may not play a significant role in Cp
clearance. Alternatively, Cp may have developed defence
mechanisms to ensure that macrophages are not recruited by
the inflammatory process that follows lung epithelial cell
infection. The lack of local MCP-1 up-regulation by Cp
infection may support the latter hypothesis. Failure to recruit
macrophages during neutrophilia could result in delayed
clearance of apoptotic neutrophils, impacting negatively
upon the resolution of inflammation. Cp infection induced
serum IgG2a and lung IgA antibodies to reLPS, indicating
that the systemic antibody response was Th1-driven and that
there was a local mucosal response.
Ectopic lymphoid tissue is a feature of chronic inflamma-
tion [29]. In this model Cp lung infection favoured develop-
ment of ectopic lymphoid tissue which secreted IgA locally
in the absence of detectable bacterial 23S DNA. Although we
cannot exclude a level of infection below the sensitivity of
the PCR-based detection method used, it may be that the
lymphoid tissue is maintained by an inflammatory process
that once initiated does not require active infection. Ectopic
lymphoid tissue formation has been reported by others after
reinfection of mice with Cp [13,14]. Here we explored a role
for infected lung epithelium in this process. Various signals
are necessary for ectopic lymphoid tissue formation in
inflammatory settings [30], but the initiating mechanisms
are not understood completely. MIP-2/CXCL2 is important
for recruitment of neutrophils and lymphocytes by gut epi-
thelial cells [18]; in lymphocyte trafficking during autoim-
mune responses [16]; and for recruitment of lymphocytes to
peripheral organs in graft-versus-host disease [17]; and has
been implicated in the neo-angiogenesis associated with
ectopic lymphoid tissue formation [19]. The finding that Cp
infection induces lung epithelial cell expression of MIP-2/
CXCL2 and secretion both in vivo and in vitro suggests a
mechanism by which both neutrophilia and lymphocytosis
may develop and formation of ectopic lymphocyte tissue
may be initiated by Cp infection of lung epithelial cells in
vivo. Ectopic lymphoid tissue which disrupts the lung archi-
tecture may itself cause signs of disease. Thus MIP-2/CXCL2
induced by Cp infection may initiate lymphocytic lung infil-
tration that can have long-term effects on tissue after clear-
ance of active infection.
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